New Heart Procedure Cuts Stroke Risk for AFib Patients Without Blood Thinners

A procedure called left atrial appendage occlusion (LAAO) is helping reduce stroke risk for people with atrial fibrillation (AFib). The treatment blocks off a small area of the heart where most dangerous blood clots form. It offers an alternative for those who cannot or prefer not to take blood-thinning drugs. Atrial fibrillation affects between 3 and 6 million adults in the US, with numbers expected to climb to 16 million by 2050. The condition raises the risk of blood clots, which can trigger an ischemic stroke—about one in seven strokes is linked to AFib. While anticoagulants cut stroke risk by half, some patients avoid these medications due to side effects or long-term concerns.

LAAO works by sealing off the left atrial appendage, a pouch in the heart where up to 90% of AFib-related clots develop. Doctors typically use a catheter-based method, inserting devices like the Watchman, Lariat, or Amulet. Before the procedure, a transesophageal echocardiogram (TEE) checks the size and position of the appendage. A 2022 study found LAAO as effective as anticoagulants in preventing major AFib complications. However, risks remain, including reactions to anaesthesia, bleeding, infection, or device-related clots.

LAAO provides a proven option for high-risk AFib patients who cannot take blood thinners. The procedure has shown strong results in lowering stroke risk, though doctors weigh its benefits against potential complications. With AFib cases rising, treatments like this may become more widely used in the coming years.